Transcriptional profiles of Campylobacter jejuni NCTC 11168 to 0.125mg/L erythromycin treatment. Campylobacter jejuni subsp. jejuni NCTC 11168 = ATCC 700819

Erythromycin is the drug of choice to treat campylobacteriosis, but resistance to this antibiotic is rising. The adaptive mechanisms employed by Campylobacter jejuni to erythromycin treatment remain unknown. The aim of this study is to determine the molecular basis underlying Campylobacter’s immediate response to Ery treatment. Overall design: The design utilized an available two color microarray slide for the entire transcriptome of Campylobacter jejuni wild type strain NCTC 11168. One hybridizations were performed: sham-treated NCTC 11168 v.s. sub-lethal dose erythromycin treated NCTC 11168. Samples were independently grown and harvested. There were three biological replicates of each sample.

红霉素（Erythromycin）是治疗弯曲杆菌病（campylobacteriosis）的首选药物，但该抗生素的耐药性正逐年攀升。目前空肠弯曲杆菌（Campylobacter jejuni）应对红霉素处理的适应性调控机制仍未明确。本研究旨在阐明弯曲杆菌对红霉素处理产生即时应答的分子基础。实验整体设计：本研究采用针对空肠弯曲杆菌野生型菌株（wild type strain）NCTC 11168全转录组（transcriptome）的商用双色微阵列芯片（two color microarray slide），仅开展一组杂交实验：以假处理组NCTC 11168菌株与经亚致死剂量（sub-lethal dose）红霉素处理的NCTC 11168菌株作为对照样本。两组样本均独立培养并收获，且每组设置3次生物学重复（biological replicates）。